uniQure NASDAQ: QURE
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands.
Name | uniQure |
Ticker | QURE |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Gene Editing - Cell Therapies |
Price | 37.53 |
52W Low/High | 35.35 / 67.74 |
Market cap | 1.7 B |
1Y Total Return |
-44.42%
Weak |
1Y Volatility |
63.34%
Average Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands.
Details
Ticker | QURE |
Name | uniQure |
ISIN | NL0010696654 |
CUSIP | |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Gene Editing - Cell Therapies |
Country | Netherlands |
Currency | U.S. Dollar |
In Index(ices) | NASDAQ Biotechnology Index |
Share as of 1/15/21
Close Price | 37.53 |
52W Low/High | 35.35 / 67.74 |
Market cap | 1.7 B |
1Y Total Return |
-44.42%
Weak |
1Y Volatility |
63.34%
Average Risk |
Beta | 1.81 |
PE (trailing) | - |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | -2,738.3% |
Cash from Op. / Cur. Liabilities | -3.71 |
Diluted Earnings / Share | -3.77 |
ROE | - |
ROIC | -417.0% |
Price / Revenue | 275.7 |
Price / Book | 7.3 |
Price / CF | -13.5 |
Current Ratio | 8.6 |
Cur.Liabilities / Tot.Liabilities | 0.3 |
Financial Leverage | 0.31 |
in Mils USD |
rolling-year up to September
|
|||||
---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | |
Revenue |
6
|
6
|
12
|
20
|
-
|
|
Gross Profit |
6
|
6
|
12
|
20
|
-
|
|
R&D |
117
|
87
|
74
|
74
|
-
|
|
EBITDA |
-152
|
-94
|
-74
|
-56
|
-
|
|
Operating Income |
-153
|
-114
|
-89
|
-80
|
-
|
|
Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
|
per Share | ||||||
Diluted avg Shares |
44
|
41
|
37
|
26
|
-
|
|
EPS exc. Extra |
-3.77
|
-2.74
|
-2.66
|
-2.61
|
-
|
|
Dividend |
-
|
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | |
Total Assets |
351
|
472
|
281
|
139
|
-
|
|
Cash, Eq & Invt ShortTerm |
279
|
403
|
240
|
89
|
-
|
|
Total Current Assets |
287
|
408
|
242
|
92
|
-
|
|
Total Non-Current Assets |
63
|
64
|
39
|
47
|
-
|
|
Intangibles |
5
|
6
|
6
|
10
|
-
|
|
Total Liabilities |
123
|
121
|
81
|
119
|
-
|
|
Total Current Liabilities |
33
|
28
|
32
|
25
|
-
|
|
Long Term Debt |
89
|
93
|
49
|
94
|
-
|
|
Shareholder equity |
228
|
350
|
200
|
20
|
-
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | |
Cash from Operations |
-124
|
-91
|
-76
|
-62
|
-
|
|
Depreciation |
10
|
7
|
12
|
8
|
-
|
|
Cash from Investing |
-9
|
-5
|
-5
|
-8
|
-
|
|
Capex |
6
|
4
|
3
|
7
|
-
|
|
Cash from Financing |
5
|
262
|
232
|
1
|
-
|
|
Stock Issued |
5
|
248
|
231
|
1
|
-
|
|
Debt (LT) Issued |
0
|
15
|
0
|
0
|
-
|
|
Free Cash Flow |
-153
|
-100
|
-68
|
-
|
-
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | |
Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
|
NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
|
Current Ratio |
8.6
|
14.3
|
7.6
|
3.6
|
-
|
|
Financial Leverage D/E |
0.31
|
0.20
|
0.10
|
1.05
|
-
|
|
Return on Capital Avg |
-417.0%
|
-408.8%
|
-508.1%
|
-522.1%
|
-
|
|
Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available